Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs AVANAFIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing nitric oxide-mediated relaxation of smooth muscle in the corpus cavernosum, increasing c GMP levels, and promoting penile erection.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Treatment of erectile dysfunction (FDA-approved),Pulmonary arterial hypertension (off-label)
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
100 mg orally once daily, taken 30-60 minutes before sexual activity. Maximum dosing frequency: once daily.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal elimination half-life approximately 6-8 hours. Clinical context: Supports once-daily dosing; steady-state reached within 5 days with no accumulation at FDA-approved dose.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily metabolized by CYP3A4, with minor contributions from CYP2C9 and CYP2C19. Subject to first-pass metabolism.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Primarily hepatic metabolism via CYP3A4 and CYP2C9, with metabolites excreted in feces (approximately 82-90%) and urine (approximately 6-8% as unchanged drug and minor metabolites).
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
4-6 L/kg; large Vd indicates extensive tissue distribution
Volume of distribution approximately 200 L (≈ 2.9 L/kg for a 70 kg individual). Clinical meaning: Indicates extensive tissue distribution, with high affinity for genital tissues.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral bioavailability approximately 15-20% due to extensive first-pass metabolism. Absolute bioavailability not determined in humans; based on animal data.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) as safety and efficacy have not been established.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Child-Pugh Class A and B: No dosage adjustment required. Child-Pugh Class C: Not recommended due to lack of data.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Not indicated for use in pediatric patients (age <18 years). Safety and efficacy not established.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
No dosage adjustment required solely based on age. However, consider lower starting dose (50 mg) in patients ≥65 years due to potential increased sensitivity and decreased clearance.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
None.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Cardiovascular risk: Not recommended in patients with unstable angina, recent MI (within 90 days), or uncontrolled arrhythmias.,Hypotension: Caution with alpha-blockers or antihypertensives; avoid in those with hypotension (BP <90/50 mm Hg).,Priapism: Advise patients to seek immediate medical attention for erections lasting >4 hours.,Hepatic impairment: Avoid use in severe hepatic impairment (Child-Pugh class C).,Renal impairment: Not recommended in patients on renal dialysis.,Visual effects: Non-arteritic anterior ischemic optic neuropathy (NAION) reported, though rare.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Concomitant use of organic nitrates (e.g., nitroglycerin, isosorbide mononitrate/dinitrate),Concomitant use of guanylate cyclase stimulators (e.g., riociguat),Hypersensitivity to avanafil or any component of the formulation,Severe hepatic impairment (Child-Pugh class C),Recent stroke or myocardial infarction (within 6 months),Patients with hypotension (BP <90/50 mm Hg)
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Avanafil can be taken with or without food. However, a high-fat meal may delay absorption and reduce peak plasma concentration, potentially prolonging time to onset. Grapefruit juice may increase avanafil levels; avoid concurrent consumption.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of teratogenicity at exposures up to 18 times the MRHD. Risk cannot be ruled out; use only if clearly needed.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Not known if excreted in human milk. No data on M/P ratio. Caution advised; consider developmental benefits of breastfeeding vs potential adverse effects.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No specific dose adjustments established; use lowest effective dose if indicated. Pharmacokinetic changes in pregnancy unknown; monitor for efficacy and adverse effects.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Avanafil is a rapid-onset PDE5 inhibitor with a Tmax of 30-45 minutes, making it suitable for on-demand use. It has minimal interaction with alpha-blockers compared to other PDE5 inhibitors, but caution is still advised. Avoid use in patients taking nitrates or those with severe hepatic impairment (Child-Pugh C). Its short half-life (5 hours) reduces the duration of side effects like headache and flushing.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take avanafil approximately 30 minutes before sexual activity, with or without food.,Do not take more than one dose in a 24-hour period.,Seek emergency medical attention if you experience an erection lasting more than 4 hours (priapism) or sudden vision loss.,Avoid alcohol or limit to small amounts as it may increase side effects like dizziness or hypotension.,Inform your doctor if you are taking any medications, especially nitrates, alpha-blockers, or antihypertensives.
No interactions on record
"Avanafil, a phosphodiesterase type 5 (PDE5) inhibitor, enhances the vasodilatory effects of nitric oxide by increasing cyclic guanosine monophosphate (cGMP) levels. Acebutolol, a cardioselective beta-blocker, reduces cardiac output and sympathetic outflow. Concurrent use may lead to additive hypotension, particularly during initiation or dose escalation, potentially causing dizziness, syncope, or orthostatic hypotension."
"Cobicistat is a potent inhibitor of CYP3A4, the primary enzyme responsible for metabolizing avanafil. Co-administration significantly increases avanafil's systemic exposure, potentially doubling its plasma concentration and half-life. This elevated exposure raises the risk of avanafil-associated adverse effects, such as hypotension, priapism, and visual disturbances, and may also enhance cobicistat's own serum levels due to shared metabolic pathways, increasing the likelihood of nephrotoxicity and other protease inhibitor-related toxicities."
"Isavuconazonium is a prodrug of isavuconazole, a triazole antifungal that inhibits CYP3A4 and CYP3A5. Coadministration with avanafil, a PDE5 inhibitor metabolized primarily by CYP3A4, can increase avanafil exposure due to reduced clearance. This may elevate the risk of avanafil-associated adverse effects such as hypotension, priapism, and visual disturbances."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs AVANAFIL, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. AVANAFIL is a PDE5 Inhibitor that works by Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing nitric oxide-mediated relaxation of smooth muscle in the corpus cavernosum, increasing c GMP levels, and promoting penile erection.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and AVANAFIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of AVANAFIL is: 100 mg orally once daily, taken 30-60 minutes before sexual activity. Maximum dosing frequency: once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and AVANAFIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. AVANAFIL is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of teratogenicity at exposures up to 18 times the MRHD. Risk cannot be ruled out; use onl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.